Published: June 25, 2015

A University of Colorado Boulder space center will fly high-tech hardware on the commercial SpaceX Dragon spacecraft launching to the International Space Station Sunday, the 50th space mission flown by BioServe Space Technologies since it was founded by NASA in 1987.

The SpaceX Dragon mission cargo includes two biomedical experiments supported by BioServe, which is headquartered in Ƶ-Boulder’s Department of Aerospace Engineering Sciences. BioServe researchers and students have flown hardware and experiments on NASA space shuttles, the International Space Station, the now-defunct Mir Space Station and on Russian, Japanese and commercial cargo rockets.

One experiment on the upcoming SpaceX mission is designed to better understand cell biology by charting the behavior of yeast cell cultures in microgravity. Because multicellular yeast colonies are similar to mammalian cell tumors, researchers hope to identify biological factors that may contribute to understanding health risks for human space crews and tumor behavior that could eventually benefit patients on Earth.

The experiment, which will be conducted in a BioServe Commercial Generic Bioprocessing Apparatus, is led by Timothy Hammond of the Durham VA Medical Center in Durham, North Carolina.

A second experiment involving BioServe hardware, being led by Allessandro Grattoni of the Houston Methodist Hospital Research Institute in Texas, is designed to help researchers better understand the mechanisms of molecular transport across tiny membrane channels. Such experiments will help scientists learn more about the release of molecules and drugs from human implants that someday could be used to treat a variety of diseases on Earth. This experiment is sponsored through the Center for the Advancement of Science in Space or CASIS, which focuses on utilizing the Space Station as a National Lab.

“We are excited to be flying once again on the SpaceX Dragon to the International Space Station,” said BioServe Business Development Manager and Education Program Director Stefanie Countryman. “We have partnered with SpaceX now on seven missions, and we feel that biomedical experiments like the ones we are flying have the potential to have a positive health impact for both spacefarers and people on Earth.”

BioServe has successfully collaborated with NASA, industry and other organizations to conduct ground- and space-based research to support the development of new scientific breakthroughs and technologies that benefit human space exploration and have commercially viable Earth-based applications. Since its inception BioServe has partnered with over 100 companies and performed dozens of NASA-sponsored investigations, said BioServe Director Louis Stodieck.

“We continually are searching for spaceflight opportunities and new ways of conducting experiments in microgravity that will push the boundaries of both research and education,” he said.

SpaceX was founded in 2002 by entrepreneur Elon Musk to manufacture and launch rockets and spacecraft. SpaceX is the only commercial company with the capability to dock spacecraft with ISS and return them to Earth.

SpaceX will once again attempt to land the first stage of the Falcon 9 rocket upright on a football-field sized floating barge in the Atlantic Ocean after it propels the Dragon spacecraft toward orbit.

For more information on BioServe visit . For more information on the Department of Aerospace Engineering Sciences visit .

Contact:
Louis Stodieck, 303-492-4010
stodieck@colorado.edu
Stefanie Countryman, 303-735-5308
countrym@colorado.edu
Malinda Miller-Huey, Ƶ-Boulder media relations, 303-492-3115
malinda.miller-huey@colorado.edu

An illustration of the Dragon spacecraft being launched by SpaceX aboard a Falcon 9 rocket, which will carry hardware designed and built by Ƶ-Boulder to the International Space Station to support biomedical experiments. Image courtesy SpaceX.

“We continually are searching for spaceflight opportunities and new ways of conducting experiments in microgravity that will push the boundaries of both research and education,” said BioServe Director Louis Stodieck.